Home > others & > Tigecycline

Tigecycline

替加环素,GAR-936,GAR936,GAR 936

Tigecycline 是首创的广谱抗生素，对多种抗生素抗性菌同样有效。

目录号
EY0649
EY0649
EY0649
EY0649
纯度
99.69%
99.69%
99.69%
99.69%
规格
1 mg
5 mg
10 mg
50 mg
原价
215
512
819
1900
售价
215
512
819
1900
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Tigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Livermore DM, et al. J Antimicrob Chemother, 2005, 56(4), 611-614.
    [2] Bhattacharya M, et al. Tigecycline. J Postgrad Med. 2009 Jan-Mar;55(1):65-8.
    [3] Seputiene V, et al. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria? Medicina (Kaunas). 2010;46(4):240-8.

    分子式
    C29H39N5O8    		 分子量
    585.65    		 CAS号
    220620-09-7    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    100 mg/mL    		 Water
    100 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02931526 Bacterial Infection|Critically Ill Drug: Tigecycline Zhujiang Hospital 2016-08-01 2016-10-10
    NCT01342731 Antibiotic Resistant Infection Drug: Tigecycline Mahidol University Phase 4 2011-07-01 2012-01-16
    NCT01560143 Obesity Drug: Tigecycline Manjunath Prakash Pai|Pfizer|University of Michigan Phase 4 2012-03-01 2016-12-16
    NCT01789905 Intra-Abdominal Infections|Skin Disease, Infectious Drug: Tigecycline (Tygacil) Pfizer 2013-04-15 2017-03-23
    NCT00406237 Liver Cirrhosis, Biliary Drug: tigecycline Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2006-12-01 2011-04-01
    NCT00419991 Staphylococcal Infections Drug: Tigecycline CPL Associates|Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2007-01-01 2011-06-21
    NCT01332786 Acute Myeloid Leukemia Drug: Tigecycline University Health Network, Toronto|University of Kansas|Memorial Sloan Kettering Cancer Center|University of California, Los Angeles Phase 1 2011-03-01 2015-04-14
    NCT02191475 Abdominal Infection Drug: glycopeptide plus carbapenem|Drug: Haizheng Li Xing 庐 plus tazocin 庐 Tianjin Medical University Cancer Institute and Hospital|Zhejiang Hisun Pharmaceutical Co. Ltd. Phase 2|Phase 3 2014-05-01 2014-07-13
    NCT00827541 Intra-Abdominal Infections|Skin Disease, Infectious|Soft Tissues Infections Drug: Tigecycline Pfizer 2008-08-01 2011-12-23
    NCT01401023 Diarrhea|Clostridium Difficile Drug: Tigecycline Gary E. Stein, Pharm.D.|Pfizer|Michigan State University 2011-07-01 2015-10-12
    NCT00600600 Mycobacterium Abscessus Lung Disease|Rapidly Growing Mycobacterial Lung Disease Drug: Tigecycline The University of Texas Health Science Center at Tyler|Wyeth is now a wholly owned subsidiary of Pfizer Phase 2 2002-04-01 2008-01-14
    NCT03034174 Septic Shock|Antibiotic Resistant Infection|Critical Illness Medical University of Lublin 2017-01-15 2017-01-26
    NCT01072539 Complicated Skin and Skin Structure Infections|Complicated Intra-abdominal Infections|Community-Acquired Bacterial Pneumonia Drug: tigecycline Pfizer 2010-05-01 2016-04-21
    NCT00376324 Healthy Subjects Drug: Tigecycline Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2006-09-01 2009-07-08
    NCT01287793 Healthy Drug: tigecycline|Drug: tigecycline|Drug: moxifloxacin|Drug: 100 mL 0.9% Sodium Chloride intravenous|Drug: placebo Pfizer Phase 1 2011-01-01 2011-05-23
    NCT00488488 Infection Drug: tigecycline Pfizer 2006-11-01 2011-07-20
    NCT00911573 Skin Diseases|Infection Drug: Tigecycline|Drug: Clindamycin (or Vancomycin if needed) Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2011-08-01 2012-06-05
    NCT01602874 Community Acquired Bacterial Pneumonia|Complicated Intra-Abdominal Infection Drug: Tigecycline|Drug: Tigecycline|Drug: cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|Drug: CAP: Ceftriaxone, plus if applicable oral clarithromycin Pfizer Phase 3 2011-01-01 2013-02-21
    NCT00914888 Community Acquired Bacterial Pneumonia|Complicated Intra-Abdominal Infection Drug: Tigecycline|Drug: Tigecycline|Drug: cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|Drug: CAP: Ceftriaxone, plus if applicable oral clarithromycin Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2011-01-01 2012-06-05
    NCT00488761 Skin Diseases, Infectious Drug: Tigecycline Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2006-07-01 2007-12-21
    NCT00488306 Abdominal Abscess Drug: tigecycline Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2006-08-01 2009-07-06

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：